Showing results (301-310 of 386) with videos related to

Sort By:
Pageof 39
BJU International|March 8, 2013
Gender-specific effect of smoking on upper tract urothelial carcinoma outcomesMichael Rink, Evanguelos Xylinas, Quoc-Dien Trinh, et al.
Scientific Reports|April 29, 2016
Cancer stem cells are underestimated by standard experimental methods in clear cell renal cell carcinomaCraig Gedye, Danylo Sirskyj, Nazleen C Lobo, et al.
Urologic Oncology|September 21, 2020
The suggested chemopreventive association of metformin with prostate cancer in diabetic patientsHanan Goldberg, Faizan K Mohsin, Alejandro Berlin, et al.
Clinical Genitourinary Cancer|August 9, 2023
Addition of Cribriform and Intraductal Carcinoma Presence to Prostate Biopsy Reporting Strengthens Pretreatment Risk Stratification Using CAPRA and NCCN ToolsMichelle R Downes, Kristen N Liu, Yanhong Yu, et al.
The Journal of Urology|June 24, 2026
Oncological Outcomes of Non-Muscle Invasive Bladder Cancer in Patients Aged ≤45: A Retrospective Matched Cohort StudyMarie-Pier St-Laurent, Shayan Din, Joseph Moryousef, et al.
Urology|September 6, 2019
Age Differences in Patient-reported Psychological and Physical Distress Symptoms in Bladder Cancer Patients - A Cross Sectional StudyRami Ajaj, Alejandro Berlin, Zachary Klaassen, et al.
Urologic Oncology|January 26, 2023
Age related differences in primary testicular lymphoma: A population based cohort studyMohamad B Berjaoui, Jaime O Herrera-Caceres, Tiange Li, et al.
Cardio-Oncology (London, England)|March 29, 2025
Addressing cardiovascular risks with a goal to prevent cardiovascular complications in patients undergoing antihormonal therapy for prostate cancerNishant P Shah, Avinash Singh, Tia Higano, et al.
Radiology|May 25, 2021
Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate CancerDominik Deniffel, Gerard M Healy, Xin Dong, et al.
Clinical Genitourinary Cancer|July 16, 2026
Long-Term Outcomes of Neoadjuvant Chemotherapy (NAC) Prior to Bladder-Sparing Trimodality Therapy (TMT) for Patients With Muscle-Invasive Bladder Cancer (MIBC)Meghan E Mahoney, Di Maria Jiang, Nely Díaz-Mejía, et al.
Pageof 39